TRAVELERS COMPANIES, INC.·4

Jan 26, 4:25 PM ET

Klenk Jeffrey P. 4

4 · TRAVELERS COMPANIES, INC. · Filed Jan 26, 2026

Research Summary

AI-generated summary of this filing

Updated

Travelers (TRV) EVP Jeffrey P. Klenk Exercises Options, Sells Shares

What Happened
Jeffrey P. Klenk, Executive Vice President and President, Bond & Specialty Insurance at Travelers (TRV), exercised stock options and immediately sold the resulting shares on Jan 23, 2026. He exercised 4,912 options at $140.85 ($691,855) and 11,800 options at $132.58 ($1,564,444), acquiring a total of 16,712 shares for a combined exercise cost of $2,256,299. Those 16,712 shares were sold in the open market at a weighted average price of $279.77 for total proceeds of $4,675,593 (net pre-tax proceeds ≈ $2,419,294).

Key Details

  • Transaction date: January 23, 2026.
  • Exercises (code M): 4,912 shares @ $140.85 (acquired for $691,855) and 11,800 shares @ $132.58 (acquired for $1,564,444).
  • Sale (code S): 16,712 shares sold in the open market @ weighted avg $279.77 for $4,675,593. Footnote F1 notes sale prices ranged $279.60–$280.25; the filer will provide a breakdown on request.
  • Two derivative-disposition lines at $0.00 reflect the conversion/closing out of the derivative instruments as part of the exercise.
  • Shares owned after the transactions: not specified in the provided filing details.
  • Filing timeliness: Report filed Jan 26, 2026 for a Jan 23 transaction (timely under Form 4 rules).

Context
This was an exercise of options followed by an immediate sale of the acquired shares (a common cashless or sell-to-cover pattern). Exercises convert derivative instruments into common shares (M), and the subsequent open-market sale (S) realized the gains; such transactions are typically routine and do not by themselves indicate the insider’s ongoing view of the company.

Insider Transaction Report

Form 4
Period: 2026-01-23
Klenk Jeffrey P.
EVP & Pres., Bond & Spec. Ins.
Transactions
  • Exercise/Conversion

    Common Stock

    2026-01-23$140.85/sh+4,912$691,85510,987.303 total
  • Exercise/Conversion

    Common Stock

    2026-01-23$132.58/sh+11,800$1,564,44422,787.303 total
  • Sale

    Common Stock

    [F1]
    2026-01-23$279.77/sh16,712$4,675,5936,075.303 total
  • Exercise/Conversion

    Stock Options (Right to Buy)

    2026-01-234,9120 total
    Exercise: $140.85From: 2021-02-06Exp: 2028-02-06Common Stock (4,912 underlying)
  • Exercise/Conversion

    Stock Options (Right to Buy)

    2026-01-2311,8009,016 total
    Exercise: $132.58From: 2023-02-04Exp: 2030-02-04Common Stock (11,800 underlying)
Footnotes (1)
  • [F1]Represents the weighted average sales price for increments ranging from $279.60 to $280.25. The Reporting Person undertakes to provide upon request by the Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Signature
/s/Wendy C. Skjerven, by power of attorney|2026-01-26

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT